PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) Clinical Trials in Durham, North Carolina

A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)